Companies in #Neuroendocrine Tumors
Found 2 companies operating in this sector.
Crinetics Pharmaceuticals is a public biopharmaceutical company developing and commercializing oral, small-molecule therapies for endocrine diseases and endocrine-related tumors.
Molecular Partners AG is a clinical-stage biotechnology company founded in 2004 as a spin-off from the University of Zurich and headquartered in Zurich-Schlieren, Switzerland, with US operations in Concord, Massachusetts. The company pioneered DARPin (Designed Ankyrin Repeat Protein) therapeutics. In October 2026, Molecular Partners announced a strategic pivot to transform into a dedicated targeted radiopharmaceuticals biotech, prioritizing its lead clinical DLL3 Radio-DARPin candidate MP0712 co-developed with Orano Med, while initiating a restructuring cutting up to 44% of headcount (no more than 55 roles).